Crovalimab: First Approval.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products.mAbs
   Pooled it
2. Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic.mAbs · 2026
   Article
3. The evolving landscape of complement therapeutics in rheumatology.Annals of the rheumatic diseases · 2026
   Review
4. Rethinking Sickle Cell Disease as a Systemic Vasculopathy.Cells · 2026
   Review
5. Integrative miRNA-mRNA Network and Molecular Dynamics-Based Identification of Therapeutic Candidates for Paroxysmal Nocturnal Hemoglobinuria.Pharmaceuticals (Basel, Switzerland) · 2026
   Article
6. Global perspectives on lupus nephritis: a review of clinical trials and therapeutic innovations.Frontiers in immunology · 2026
   Review
7. New Anticomplement Drugs in Nephrology: Mechanism and Indication.Kidney & blood pressure research · 2026
   Review
8. The complement cascade in Alzheimer's disease: modern implications of an ancient immune protagonist.Molecular neurodegeneration · 2025
   Review
9. Antibodies to watch in 2025.mAbs · 2025
   Review
10. Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies.Diseases (Basel, Switzerland) · 2025
    Review
11. Monoclonal Antibodies (mAbs) and Proteins: The Biologic Drugs Approved by the Food and Drug Administration (FDA) in 2024.Biomedicines · 2025
    Review
12. Complement System Inhibitors in Nephrology: An Update-Narrative Review.International journal of molecular sciences · 2025
    Review
13. The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria TreatmentTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025
    Review
14. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
15. [Advances in complement inhibition therapy for paroxysmal nocturnal hemoglobinuria].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Review
16. FDA approval of crovalimab: a milestone in paroxysmal nocturnal hemoglobinuria treatment.Annals of medicine and surgery (2012) · 2025
    Article
17. Advancements in PNH treatment: crovalimab's clinical efficacy.Annals of medicine and surgery (2012) · 2024
    Article
18. Donor-Derived Cell-Free DNA (dd-cfDNA) as an Early Noninvasive Biomarker of Graft Injury in Pig-to-Monkey Islet Xenotransplantation.Xenotransplantation
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as